For instance, In September 2020, UpToDate added SGLT2 inhibitors as an option for patients with continued symptoms of HF despite the use of appropriate primary agents, whether they have type 2 diabetes or not [28]. The gene discussed is SLC5A2; the disease is hydrops fetalis.